Omid C. Farokhzad
Impact in
- Biomaterials top 0.01%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 0.01%
- Advanced Drug Delivery Systems
Papers in
-
- RNA Interference and Gene Delivery 74
- Advanced biosensing and bioanalysis techniques 61
- Biomaterials 108
- Nanoparticle-Based Drug Delivery 104
- Co-authors
- Róbert Langer (77 shared papers)Jinjun Shi (51 shared papers)Philip W. Kantoff (11 shared papers)Jeffrey M. Karp (6 shared papers)Robert Langer (2 shared papers)Seungpyo Hong (2 shared papers)Dan Peer (1 shared paper)Rimona Margalit (1 shared paper)
- Journals
- Proceedings of the National Academy of Sciences (17 papers)ACS Nano (15 papers)Nano Letters (13 papers)Angewandte Chemie International Edition (10 papers)Biomaterials (10 papers)
- Partner nations
- United StatesSaudi ArabiaChina
In The Last Decade
Omid C. Farokhzad
222 papers receiving 62.3k citations
Omid C. Farokhzad's Hit Papers
Peers
Comparison fields: 5 of 188
- Biomaterials 28.2k
- Pharmaceutical Science 4.8k
- Biomedical Engineering 27.6k
- Molecular Medicine 1.7k
- Molecular Biology 24.0k
Countries citing papers authored by Omid C. Farokhzad
This map shows the geographic impact of Omid C. Farokhzad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omid C. Farokhzad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omid C. Farokhzad more than expected).
Fields of papers citing papers by Omid C. Farokhzad
This network shows the impact of papers produced by Omid C. Farokhzad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omid C. Farokhzad. The network helps show where Omid C. Farokhzad may publish in the future.
Co-authors
The 25 scholars most cited alongside Omid C. Farokhzad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 223 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nanocarriers as an emerging platform for cancer therapy Hit paper breakdown → | 2007 | 7086 |
| 2 | Cancer nanomedicine: progress, challenges and opportunities Hit paper breakdown → | 2016 | 4679 |
| 3 | Impact of Nanotechnology on Drug Delivery Hit paper breakdown → | 2009 | 2581 |
| 4 | Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release Hit paper breakdown → | 2016 | 2308 |
| 5 | Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology Hit paper breakdown → | 2013 | 2285 |
| 6 | Cellular uptake of nanoparticles: journey inside the cell Hit paper breakdown → | 2017 | 2154 |
| 7 | Nanoparticles in Medicine: Therapeutic Applications and Developments Hit paper breakdown → | 2007 | 1936 |
| 8 | Targeted polymeric therapeutic nanoparticles: design, development and clinical translation Hit paper breakdown → | 2012 | 1366 |
| 9 | Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Hit paper breakdown → | 2006 | 1356 |
| 10 | Nanoparticle Delivery of Cancer Drugs Hit paper breakdown → | 2011 | 1253 |
| 11 | Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications Hit paper breakdown → | 2010 | 1219 |
| 12 | Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology Hit paper breakdown → | 2013 | 1207 |
| 13 | Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery Hit paper breakdown → | 2006 | 1022 |
| 14 | Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform Hit paper breakdown → | 2008 | 857 |
| 15 | Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles Hit paper breakdown → | 2008 | 811 |
| 16 | pH-Responsive Nanoparticles for Drug Delivery Hit paper breakdown → | 2010 | 803 |
| 17 | Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer Hit paper breakdown → | 2007 | 756 |
| 18 | Microfluidic Platform for Controlled Synthesis of Polymeric Nanoparticles Hit paper breakdown → | 2008 | 713 |
| 19 | Nanoparticle-Aptamer Bioconjugates Hit paper breakdown → | 2004 | 693 |
| 20 | Insight into nanoparticle cellular uptake and intracellular targeting Hit paper breakdown → | 2014 | 635 |
About Omid C. Farokhzad
Omid C. Farokhzad is a scholar working on Molecular Biology, Biomaterials, Biomedical Engineering, Immunology and Pharmaceutical Science, having authored 223 papers that have together received 63.1k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (104 papers), RNA Interference and Gene Delivery (74 papers), Advanced biosensing and bioanalysis techniques (61 papers), Nanoplatforms for cancer theranostics (31 papers), Advanced Drug Delivery Systems (20 papers), Graphene and Nanomaterials Applications (19 papers), Immunotherapy and Immune Responses (10 papers) and Microfluidic and Bio-sensing Technologies (10 papers). The work is most often cited by research in Biomaterials (28.2k citations), Pharmaceutical Science (4.8k citations), Biomedical Engineering (27.6k citations), Molecular Medicine (1.7k citations) and Molecular Biology (24.0k citations). Omid C. Farokhzad has collaborated with scholars based in United States, Saudi Arabia and China. Frequent co-authors include Róbert Langer, Jinjun Shi, Philip W. Kantoff, Jeffrey M. Karp, Robert Langer, Seungpyo Hong, Dan Peer, Rimona Margalit, Richard Wooster and Nazila Kamaly. Their work appears in journals such as Proceedings of the National Academy of Sciences, ACS Nano, Nano Letters, Angewandte Chemie International Edition and Biomaterials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.